Immunology：即将到来的日期

最近

• 企业2026/10/04@HealthDesk

  Sanofi and Regeneron Expand Their Alliance With US$1 Billion Upfront

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  开始于 2026/10/01已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 86%总体可信度: 86%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 3 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉4天前Sanofi's^[1] press release is datelined "Paris and Tarrytown, NY, October 1, 2026" and the same release was furnished to the SEC^[3].

  On 1 October 2026 Sanofi and Regeneron announced they will co-develop four new long-acting immunology antibodies; Regeneron receives US$1 billion upfront and up to US$7 billion more in milestones.

  $1B

  00
• 企业2026/10/04@EconDesk

  AbbVie Completes US$10.9 Billion Acquisition of Apogee

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/09/03已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 82%总体可信度: 82%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉32天前AbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., Sept. 3, 2026' and says AbbVie 'today announced that it has completed its acquisition of Apogee'.^[1]

  On 3 September 2026 AbbVie completed its acquisition of Apogee Therapeutics, paying US$135.11 per share in cash for a total equity value of about US$10.9 billion.

  $10.9B

  00
• 健康2026/09/23@HealthDesk

  礼来同意以最高 28.75 亿美元收购 Merida Biosciences

  Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly

  

  开始于 2026/08/31已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 88%总体可信度: 88%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉35天前新闻稿的电头为“印第安纳波利斯和马萨诸塞州剑桥，2026 年 8 月 31 日”，并称两家公司“今天宣布达成由礼来收购 Merida 的最终协议”。^[1]

  礼来同意以最高 $28.75 亿现金收购 Merida Biosciences，该公司处于 1 期阶段的 MER511 旨在清除导致格雷夫斯病和甲状腺眼病的自身抗体。

  $2.9B

  00
• 企业2026/10/04@EconDesk

  AbbVie Q2 2026: US$16.99 Billion Revenue as Skyrizi Hits US$5.5 Billion

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/07/31已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 84%总体可信度: 84%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉66天前AbbVie's^[1] release is titled 'AbbVie Reports Second-Quarter 2026 Financial Results' and dated July 31, 2026.

  AbbVie reported second-quarter 2026 net revenues of US$16.990 billion, up 10.2 percent, with Skyrizi at US$5.505 billion, Rinvoq at US$2.525 billion and Humira down to US$756 million.

  00
• 企业2026/10/04@EconDesk

  AbbVie Agrees to Buy Apogee Therapeutics for US$10.9 Billion

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/06/22已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 83%总体可信度: 83%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉105天前AbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., SAN FRANCISCO and BOSTON, June 22, 2026' and says the investor call was 'today, June 22'; BioPharm International^[4] (23 June 2026) reports the same deal.

  On 22 June 2026 AbbVie agreed to acquire Apogee Therapeutics for US$135.11 per share in cash, a total equity value of about US$10.9 billion, adding the IL-13 antibody zumilokibart for atopic dermatitis.

  $10.9B

  00